Cosciens Biopharma (TSX:CSCI) Cyclically Adjusted PB Ratio: (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:CSCI Cosciens Biopharma Inc TSX:CSCI
59 GF Score
Price C$8.00
GF Value C$9.84
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cosciens Biopharma  (TSX:CSCI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cosciens Biopharma Cyclically Adjusted PB Ratio Related Terms


Cosciens Biopharma Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Cyclically Adjusted PB Ratio Chart

Cosciens Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.04 2.33 0.63 0.28 0.20

Cosciens Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.33 0.26 0.20 0.00

TSX:CSCI vs VRTX, REGN, ALNY: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Cosciens Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Cyclically Adjusted PB Ratio falls into.


TSX:CSCI
59GF Score
Cosciens Biopharma Inc TSX:CSCI
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cosciens Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Cosciens Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/132.2623*132.2623
=0.000

Current CPI (Mar. 2026) = 132.2623.

Cosciens Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 21.867 102.002 28.354
201609 36.392 101.765 47.298
201612 37.744 101.449 49.208
201703 39.236 102.634 50.563
201706 40.809 103.029 52.388
201709 40.167 103.345 51.406
201712 38.539 103.345 49.323
201803 37.695 105.004 47.480
201806 37.364 105.557 46.817
201809 37.812 105.636 47.343
201812 37.789 105.399 47.420
201903 37.474 106.979 46.330
201906 36.997 107.690 45.439
201909 36.388 107.611 44.724
201912 36.997 107.769 45.405
202003 37.912 107.927 46.460
202006 39.989 108.401 48.791
202009 40.170 108.164 49.120
202012 39.966 108.559 48.692
202103 40.499 110.298 48.564
202106 41.187 111.720 48.760
202109 42.951 112.905 50.315
202112 45.545 113.774 52.946
202203 48.476 117.646 54.499
202206 50.098 120.806 54.849
202209 50.538 120.648 55.403
202212 52.553 120.964 57.462
202303 52.617 122.702 56.717
202306 50.362 124.203 53.630
202309 48.419 125.230 51.138
202312 45.813 125.072 48.447
202403 42.258 126.258 44.268
202406 35.205 127.522 36.514
202409 26.043 127.285 27.061
202412 17.908 127.364 18.597
202503 13.883 129.181 14.214
202506 9.168 129.892 9.335
202509 6.624 130.287 6.724
202512 4.995 130.366 5.068
202603 0.000 132.262 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Cosciens Biopharma (TSX:CSCI) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of C$8.00 is trading 18.7% below its estimated GF Value™ of C$9.84. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for TSX:CSCI:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: C$9.84 vs. price of C$8.00 (18.7% below fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the TSX:CSCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cosciens Biopharma Business Description

Other Exchanges CSCIF:USAET8:Germany
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
59GF Score

Get the complete analysis for TSX:CSCI

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$8.00
Price
C$9.84
GF Value